Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 15;20(1):759.
doi: 10.1186/s12879-020-05478-6.

French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

Cécile Brouard  1 , Josiane Pillonel  2 , Marjorie Boussac  2   3 , Victor de Lédinghen  4   5 , Antoine Rachas  3 , Christine Silvain  6 , Nathalie Lydié  2 , Stéphane Chevaliez  7   8 , Corinne Pioche  2 , Julien Durand  2 , Florence Lot  2 , Elisabeth Delarocque-Astagneau  9   10
Affiliations

French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

Cécile Brouard et al. BMC Infect Dis. .

Abstract

Background: Hepatitis C virus (HCV) elimination by 2030, as targeted by the World Health Organization (WHO), requires that 90% of people with chronic infection be diagnosed and 80% treated. We estimated the cascade of care (CoC) for chronic HCV infection in mainland France in 2011 and 2016, before and after the introduction of direct-acting antivirals (DAAs).

Methods: The numbers of people (1) with chronic HCV infection, (2) aware of their infection, (3) receiving care for HCV and (4) on antiviral treatment, were estimated for 2011 and 2016. Estimates for 1) and 2) were based on modelling studies for 2011 and on a virological sub-study nested in a national cross-sectional survey among the general population for 2016. Estimates for 3) and 4) were made using the National Health Data System.

Results: Between 2011 and 2016, the number of people with chronic HCV infection decreased by 31%, from 192,700 (95% Credibility interval: 150,900-246,100) to 133,500 (95% Confidence interval: 56,900-312,600). The proportion of people aware of their infection rose from 57.7 to 80.6%. The number of people receiving care for HCV increased by 22.5% (representing 25.7% of those infected in 2016), while the number of people on treatment increased by 24.6% (representing 12.1% of those infected in 2016).

Conclusions: This study suggests that DAAs substantially impact CoC. However, access to care and treatment for infected people remained insufficient in 2016. Updating CoC estimates will help to assess the impact of new measures implemented since 2016 as part of the goal to eliminate HCV.

Keywords: Cascade of care; Diagnosis; Direct-acting antivirals; Elimination; France; Hepatitis C; Management; Prevalence; Treatment.

PubMed Disclaimer

Conflict of interest statement

Stéphane Chevaliez has received research grants from Gilead and has served as an advisor and/or speaker for Abbott, Cepheid, Hologic.

Victor de Lédinghen has received consulting fees from Gilead, AbbVie.

Christine Silvain has served as a speaker for AbbVie, Gilead.

All these grants and fees were independent of the work presented in this article.

None for the other authors.

Figures

Fig. 1
Fig. 1
Schematic overview of the principle of the multi-parameter evidence synthesis method in 2011. Pop. = population; prev. = prevalence
Fig. 2
Fig. 2
Schematic overview of the projection modelling used to estimate the number of people unaware of their infection in 2011. Each year, individuals enter or leave the pool of the chronically-infected undiagnosed population
Fig. 3
Fig. 3
Estimated chronic HCV cascade of care in 2011 and in 2016 in mainland France according to main analysis and analysis with age range adjustment. Note: Percentages are calculated from the estimated numbers of people with chronic HCV infection
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization . Resolution of the 67th world health assembly on viral hepatitis (WHA 67.6) Geneva: World Health Organization; 2014.
    1. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. Geneva; 2016. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pd....
    1. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793–800. doi: 10.1093/cid/ciq243. - DOI - PMC - PubMed
    1. Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, et al. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service. PLoS One. 2015;10:e0142770. doi: 10.1371/journal.pone.0142770. - DOI - PMC - PubMed
    1. Patel RC, Vellozzi C, Smith BD. Results of hepatitis C birth-cohort testing and linkage to Care in Selected U.S. sites, 2012–2014. Public Health Rep. 2016;131 Suppl 2:12–19. doi: 10.1177/00333549161310S203. - DOI - PMC - PubMed

Substances